<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Zivin, Justin</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Results of NEST-2: A Double-Blind, Randomized, Phase III Study Evaluating the Safety and Efficacy of Transcranial Laser Therapy for Acute Ischemic Stroke within 24 Hours of Stroke Onset</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">Results from the NeuroThera® Effectiveness and Safety Trial-2 [NEST-2; NCT00419705] show no difference in efficacy between transcranial laser therapy and sham treatment for the treatment of acute ischemic stroke when applied within 24 hours of diagnosis.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>